

WICK, WOLFGANG, PROF. DR. MED.

General Information



Chairman /Head

University Hospital Heidelberg, Department of Neurology/Neurooncology
Clinical Cooperation Unit Neurooncology, DKFZ
Im Neuenheimer Feld 400, 69120 Heidelberg, Germany

Academic Education & Qualification

Year(s)	Education
2003	Board certification in Neurology
1990-1997	Medical School, University of Bonn (Germany), Harvard Medical School, Boston (USA), King's College London (Great Britain)

Scientific Education & Qualification

Year(s)	Education
2003	Habilitation and venia legendi for Neurology
1998	MD thesis, Institute for Neuropathology (Prof. Dr. O.D. Wiestler), University of Bonn

Professional experience

Year(s)	Experience
2014	Chairman General Neurology, University of Heidelberg
2007-2014	Chairman Dep. of Neurooncology/NCT and Professor of Clinical Neurooncology, University of Heidelberg
2006	Vice Chairman, Dep. of General Neurology, University of Tübingen
since 2004	Attending in Neurology
1999-2002	Internship and Resident, Department of Neurology and Psychiatry, University of Tübingen

OTHER Qualifications/roles/responsibilities/Awards/Honors (selection)

Year(s)	
2019-2023	SFB Spokesperson UNITE 1389 "Understanding and targeting resistance in glioblastoma"
2016-2018	President EANO
2015	German Cancer Award (Translational Part)
2014	Chair of the NOA
2010-2014	Member of the Board of Directors European Cancer Organization (ECCO)
2010	Member of the Board of Directors at the NCT
2009	Key Note Lecture World Federation of Neurooncology Meeting, Japan Fellow of the Faculty of the 1000 Medicine
2009	Member of the of the Grant Application Council for Young Scientists, German Cancer Aid
2009-2015	Chairman of the EORTC Brain Tumor Group
2006	Pette Award of the German Society of Neurology
2005	Sibylle-Assmus Award for Neurooncology

SELECTED PUBLICATIONS

1. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M, Hodecker S, Osswald M, Meisner C, Hielscher T, Rübmann P, Pfenning PN, Ronellenfisch M, Kempf T, Schnölzer M, Abdollahi A, Lang F, Bendszus M, von Deimling A, Winkler F, Weller M, Vajkoczy P, Platten M, Wick W. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. **Proc Natl Acad Sci U S A** 2014;111(1):409-14.
2. Wick W, Fricke H, Junge K, Kobayakov G, Martens T, Heese O, Wiestler B, Schliesser MG, von Deimling A, Pichler J, Vetlova E, Harting I, Debus J, Hartmann C, Kunz C, Platten M, Bendszus M, Combs SE. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. **Clin Cancer Res** 2014;20(24):6304-13
3. Wiestler B, Capper D, Sill M, Jones DT, Hovestadt V, Sturm D, Koelsche C, Bertoni A, Schweizer L, Korshunov A, Weiß EK, Schliesser MG, Radbruch A, Herold-Mende C, Roth P, Unterberg A, Hartmann C, Pietsch T, Reifenberger G, Lichter P, Radlwimmer B, Platten M, Pfister SM, von Deimling A, Weller M, Wick W. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. **Acta Neuropathol** 2014;128(4):561-71
4. Lemke D, Pledl HW, Zorn M, Jugold M, Green E, Blaes J, Löw S, Hertenstein A, Ott M, Sahm F, Steffen AC, Weiler M, Winkler F, Platten M, Dong Z, Wick W. Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. **Oncotarget** 2016 Aug 30;7(35):56713-56725
5. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper M, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, for the Neurooncology Working Group (NOA) of the German Cancer Society Chemotherapy versus radiotherapy for malignant astrocytoma in the elderly. **Lancet Oncol** 2012;13(7):707-15
6. Wick W, Fricke H, Junge K, Kobayakov G, Martens T, Heese O, Wiestler B, Schliesser MG, von Deimling A, Pichler J, Vetlova E, Harting I, Debus J, Hartmann C, Kunz C, Platten M, Bendszus M, Combs SE. A phase II, randomised, study of weekly APG101 + reirradiation versus reirradiation in progressive glioblastoma. **Clin Cancer Res** 2014;20(24):6304-13
7. Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. **Clin Cancer Res** 2015;21(9):2057-64
8. Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, Kosch M, Weller M, Stupp R, Roth P, Golfopoulos V, Frenel JS, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Hegi ME. Phase II Study of Radiotherapy and Temozolomide versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). **Clin Cancer Res** 2016;22(19):4797-4806
9. Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ. EORTC 26101 trial of lomustine with or without bevacizumab in progressive glioblastoma. **New Engl J Med** 2017; 377(20):1954-1963
10. Hilf N, Kuttruff-Coqui S,..., Platten M,..., von Deimling A,...Bunse L,...Wick W. Actively personalized vaccination trial for newly diagnosed glioblastoma. **Nature** 2019; 565(7738):240-245.

PATENTS

- Means and methods for treating and/or preventing natural Ahr ligand-dependent cancer (WO 2013034685 A1 -)
- Methods for the diagnosis and prognosis of a brain tumor (diagnostic use of IDH1 R132H mutation specific antibody; EP2256214)
- Parvovirus – checkpoint inhibitor combinations (P-1238 / 33-15ERF)
- Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers (IDH immunotherapy; WO 2013/102641 A1, PCT/EP2013/050048)

- Treatment of Kynurenin-producing Tumors with AhR Antagonists (PCT/EP2012/067504, US 2014/0294860 A1, WO2013/034685, US 9,593,062 B2)
- Method for the Detection of Antigen Presentation 8 DKFZ, P1203, EPA 14190538.0)
- Method for predicting responsiveness of a cancer disease to treatment on the basis of DNA methylation (WO 2015/107105; PCT/EP2015/064762)
- Means and methods for treating or diagnosing H3.3 K27M mutant-positive cancers (UKH 14-15ERF; DKFZ, P1248; PCT/EP2016/066563)
- Agents for use in the treatment of glioma (WO 2017020982 A1)